Humatrope somatropin brand information and questions about future availability.
This page provides historical product information and does not offer Humatrope for purchase. Lilly’s distribution-end announcement concerns the United States.
Eli Lilly has announced it will discontinue Humatrope distribution in the United States on December 31, 2026, with residual stock potentially available afterward.
Lilly states it has permanently discontinued production and supply of Humatrope and will permanently discontinue distribution on December 31, 2026. Limited inventory may remain until exhausted.
Patients currently prescribed Humatrope should discuss potential alternatives with their clinician rather than changing products or doses independently.
Read the manufacturer announcement →
This is Lilly’s U.S. distribution announcement.
Do not interpret a discontinuation notice as evidence that another pen, dose, or concentration can be substituted directly. Device systems and excipients can differ by product and country.
This page is an educational archive and does not offer Humatrope for sale.
The manufacturer states December 31, 2026.
Lilly notes limited residual stock may remain until exhausted.
Official manufacturer and regulatory sources for the clinical and technical facts discussed here.
Find the pharmaceutical brand, strength, and presentation that you are researching. Our team can explain the next steps and physician consultation pathway.
Contact patient support →Humatrope is a somatropin product associated with Eli Lilly. Its status is being tracked because Lilly announced an end to U.S. distribution by December 31, 2026. This page is informational rather than a featured current offer.
Explore the current daily somatropin brand comparison for other manufacturers.
Start with the product. Then decide whether you want to speak with our patient support team.